Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin

Diabetes Technology and Therapeutics

Volumn 16, Issue 3, 2014, Pages 137-144

  Mudaliar, Sunder ^a   Henry, Robert R ^a   Boden, Guenther ^b   Smith, Steven ^c   Chalamandaris, Alexandros Georgios ^d   Duchesne, Dominique ^d   Iqbal, Nayyar ^d   List, James ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FLORIDA HOSPITAL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN SECRETAGOGUE; METFORMIN; PLACEBO; UNCLASSIFIED DRUG; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; C PEPTIDE; CREATININE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; BODY WEIGHT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSURIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION; VAGINITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CREATININE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84896816933     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0167     Document Type: Article

References (18)

1. DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835, ix.
2. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian JP: Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008; 34(Suppl 2):S43-S48.
3. Boden G, Ruiz J, Kim CJ, Chen X: Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 1996;270:E251-E258.
4. Del Prato S: Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009;26:1185-1192.
5. Kaiser N, Leibowitz G, Nesher R: Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003;16:5-22.
6. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA: Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-1044.
7. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515.
8. Zinker B, Ma X, Liu H, Cai C, Ponticiello R, Zalaznick J, Washburn W, Whaley J: Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats [abstract 1031-P]. Diabetes 2011;60(Suppl 1):A283.
9. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-2233.
10. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi TP, Armstrong D, Kim B, Sha X, Henry RR: Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 2002;25:1597-1602.
11. DeBodo RC, Steele R, Altszuler N, Dunn A, Bishop JS: On the hormonal regulation of carbohydrate metabolism: studies with C14 glucose. Recent Prog Horm Res 1963;19:445-488.
12. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68: 1456-1467.
13. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN: MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003; 5:1003-1015.
14. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinemiceuglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987;36: 914-924.
15. Jequier E, Felber JP: Indirect calorimetry. Baillieres Clin Endocrinol Metab 1987;1:911-935.
16. Rizza RA, Cryer PE, Gerich JE: Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 1979;64:62-71.
17. Nauck MA, del PS, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-2022.
18. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.